Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 10, 2000 - Issue 4
Submit an article Journal homepage
78
Views
44
CrossRef citations to date
0
Altmetric
Review

The potential therapeutic value of nociceptin receptor agonists and antagonists

Jean-Claude Meunier Institut de Pharmacologie et de Biologie Structurale, Centre National de la Recherche Scientifique, 205 route de Narbonne, 31077 Toulouse Cédex 4, France. [email protected]
Pages 371-388 | Published online: 25 Feb 2005

Bibliography

  • EVANS CJ, KEITH DE, MORRISON H, MAGENDZO K, RH: Cloning of a delta-opioid receptor by functional expression. Science (1992) 258:1952–1955.
  • ••First molecular cloning of a member of the opioid receptorfamily.
  • KIEFFER BL, BEFORT K, GAVERIAUX-RUFF C, HIRTH CG: delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characteri-zation. Proc. Natl. Acad. Sci. USA (1992) 89:12048–12052.
  • ••First molecular cloning of a cDNA encoding an opioidreceptor.
  • KIEFFER BL: Molecular aspects of opioid receptors. In: Pain, Handbook of Experimental Pharmacology. Dickenson A, Besson J-M (Eds.), Springer-Verlag, Berlin Heidelberg (1997) 130:281–303.
  • MOLLEREAU C, PARMENTIER M, MAILLEUX P et al: ORL1, a novel member of the opioid receptor family: cloning, functional expression and localization. FEBS Lett. (1994) 341:33–38.
  • •Discovery of an orphan opioid receptor-like receptor (see also [5–121) and demonstration of its negative coupling to adenylyl cyclase.
  • FUKUDA K, KATO S, MORI K et al.: cDNA cloning and regional distribution of a novel member of the opioid receptor family. FEBS Lett. (1994) 343:42–46.
  • CHEN Y, FAN Y, LIU J, MESTEK A, TIAN M, KOZAK C. A, YU: Molecular cloning, tissue distribution and chromo-somal localization of a novel member of the opioid receptor gene family. FEBS Lett. (1994) 347:279–283.
  • BUNZOW JR, SAEZ C, MORTRUD M et al.: Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEES Lett. (1994) 347:284–288.
  • WANG JB, JOHNSON PS, IMAI Y et al.: cDNA cloning of anorphan opiate receptor gene family member and its splice variant. FEBS Lett. (1994) 348:75–79.
  • WICK MJ, MINNERATH SR, LIN X, ELDE R, LAW PY, LOHHH: Isolation of a novel cDNA encoding a putative membrane receptor with high homology to the cloned mu-, delta-, and kappa-opioid receptors. Brain Res. Mol. Brain. Res. (1994) 27:37–44.
  • LACHOWICZ JE, SHEN Y, MONSMA FJ JR, SIBLEY DR: Molecular cloning of a novel G protein-coupled receptor related to the opiate receptor family. Neurochem. (1995) 64:34–40.
  • NISHI M, TAKESHIMA H, MORI M, NAKAGAWARA K, TAKEUCHI T: Structure and chromosomal mapping of genes for the mouse kappa-opioid receptor and an opioid receptor homologue (MOR-C). Biochem. Biophys. Res. Commun. (1994) 205:1353–1357.
  • HALFORD WP, GEBHARDT BM, CARR DJ: Functional roleand sequence analysis of a lymphocyte orphan opioid receptor. I Neuroimmunol. (1995) 59:91–101.
  • WICK MJ, MINNERATH SR, ROY S, RAMAKRISHNAN S, LOH HH: Expression of alternate forms of brain opioid orphan receptor mRNA in activated human peripheral blood lymphocytes and lymphocytic cell lines. Brain Res. Mol. Brain. Res. (1995) 32:342–347.
  • MEUNIER J-C, MOLLEREAU C, TOLL L eta].: Isolation and structure of the endogenous agonist of opioid receptor- like ORLI receptor. Nature (1995) 377:532–535.
  • ••From orphan receptor gene to endogenous ligand, aclearcut example of the successful implementation of genomics. Discovery of nociceptinorphaninFQ) and demonstration of nociceptin precursor.
  • REINSCHEID RK, NOTHACKER HP, BOURSON A et al.: FQ: a neuropeptide that activates an opioid-like G protein- coupled receptor. Science (1995) 270:792–794.
  • ••From orphan receptor gene to endogenous ligand, aclearcut example of the successful implementation of functional genomics. Discovery of orphanin FQ (. nociceptin).
  • JULIUS D: Pharmacology: home for an orphan endorphin. Nature (1995) 377:476.
  • ROWE PM: Excitement over orphanin FQ/nociceptin.Lancet (1996) 347:606.
  • HENDERSON G, MCKNIGHT AT: The orphan opioid receptor and its endogenous ligand-nociceptin! orphanin FQ. Trends Pharmacol. Sci. (1997) 18:293–300.
  • MEUNIER J-C: Nociceptin/orphanin FQ and the opioidreceptor-like ORL1 receptor. Eur. I Pharmacol. (1997) 340:1–15.
  • DARLAND T, HEINRICHER MM, GRANDY DK: Orphanin/nociceptin: a role in pain and analgesia, but so much more. Trends Neurosci. (1998) 21:215–221.
  • •Excellent overview of the role of nociceptin/orphanin FQ in pain and analgesia, emphasising the importance of neuronal circuitry.
  • DARLISON MG, GRETEN FR, HARVEY RJ et al.: Opioid from a lower vertebrate (Catostomus commersom): sequence, pharmacology, coupling to a G protein-gated inward-rectifying potassium channel (GIRK1), and evolution. Proc. Natl. Acad Sci. USA (1997) 94:8214–8219.
  • LI X, KEITH DE JR; EVANS CJ: Multiple opioid receptor-like genes are identified in diverse vertebrate phyla. FEBS Lett. (1996) 397:25–29.
  • PAN YX, XU J, PASTERNAK GW: Structure and charac-terization of the gene encoding a mouse kappa3-related opioid receptor. Gene (1996) 171:255–60.
  • PELUSO J, LAFORGE KS, MATTHES HW, KREEK MJ, KIEFFER BL, GAVERIAUX-RUFF C: Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells. Neuroimmunol (1998) 81:184–192.
  • ANTON B, FEIN J, TO T, LI X, SILBERSTEIN L, EVANS CJ: Immunohistochemical localization of ORL-1 in the central nervous system. I Comp. Neurol 368:229–251.
  • MONTEILLET-AGIUS G, FEIN J, ANTON B, EVANS CJ: ORL-1 and mu opioid receptor antisera label different fibers in areas involved in pain. 1 Comp. Neurol (1998) 399:373–383.
  • BUTOUR J-L, MOISAND C, MAZARGUIL, H, MOLLEREAU,, MEUNIER JC: Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids. Eur. I Pharmacol (1997) 321:97–103.
  • •Shows that the opiate lofentanil is also a potent agonist of the ORLI receptor. Suggests 4-anilinopiperidine as a leader motif for the design of non-peptidic ORLI receptor ligands.
  • SAITO Y, MARUYAMA K, SAIDO TC, KAWASHIMA S: N23K, a gene transiently up-regulated during neural differentiation, encodes a precursor protein for a newly identified neuropeptide nociceptin. Biochem. Biophys. Res. Commun. (1995) 217:539–545.
  • •CAMP induces expression of the pp-noc gene.
  • HOUTANI T, NISHI M, TAKESHIMA H, NUKADA T, SUGIMOTO T: Structure and regional distribution of nociceptin/orphanin FQ precursor. Biochem. Biophys. Res. Commun. (1996) 219:714–719.
  • PAN YX, XU J, PASTERNAK GW: Cloning and functionalexpression of a cDNA encoding a mouse brain orphanin FQ/nociceptin precursor. Biochem. 1 (1996) 315:11–13.
  • MOLLEREAU C, SIMONS MJ, SOULARUE P et al: Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. Proc. Natl. Acad. Sci. USA (1996) 93:8666–8670.
  • NOTHACKER HP, REINSCHEID RK, MANSOUR A et al: Primary structure and tissue distribution of the FQ precursor. Proc. Natl. Acad. Sci. USA (1996) 93:8677–8682.
  • SAITO Y, MARUYAMA K, KAWANO H et al.: Molecularcloning and characterization of a novel form of neuropeptide gene as a developmentally regulated molecule. 1 Biol. Chem. (1996) 271:15615–15622.
  • XIE GX, ITO E, MARUYAMA K et al: The promoter regionof human prepro-nociceptin gene and its regulation by cyclic AMP and steroid hormones. Gene (1999) 238:427–436.
  • •Oestrogens and glucocorticoids regulate expression of the pp-noc gene.
  • SIRIANNI MJ, FUJIMOTO KI, NELSON CS, PELLEGRINO MJ, RG: Cyclic AMP analogs induce synthesis, processing, and secretion of prepro-nociceptin! orphanin FQ-derived peptides by NS20Y neuroblas-toma cells. DNA Cell. Biol. (1999) 18:51–58.
  • •A promising cellular model for studying the metabolism of pp-noc.
  • BUZAS B, ROSENBERGER J, COX BM: Activity and cyclicAMP-dependent regulation of nociceptin/orphanin FQ gene expression in primary neuronal and astrocyte cultures. I Neurochem. (1998) 71:556–563.
  • NEAL CR, MANSOUR A, REINSCHEID RK, NOTHACKER HP, CIVELLI O. WATSON SJ, JR.: Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat. I Comp. Neurol (1999) 406:503–547.
  • BOOM A, MOLLEREAU C, MEUNIER J-C et al: Distributionof the nociceptin and nocistatin precursor transcript in the mouse central nervous system. Neuroscience (1999) 91:991–1007.
  • RIEDL M, SHUSTER S, VULCHANOVA L, WANG J, LOH HH,ELDE R: Orphanin FQ/nociceptin-immunoreactive nerve fibers parallel those containing endogenous opioids in rat spinal cord. NeuroReport (1996) 7:1369–1372.
  • SCHULZ S, SCHREFF M, NUSS D, GRAMSCH C, HOLLT V:Nociceptin/orphanin FQ and opioid peptides show overlapping distribution but not co-localization in pain-modulatory brain regions. NeuroReport (1996) 7:3021–3025.
  • MA L, CHENG ZJ, FAN GH, CAI YC, JIANG LZ, PEI G:Functional expression, activation, and desensitization of opioid receptor-like receptor ORL1 in neuroblas-toma x glioma NG108-15 hybrid cells. FEBS Lett. (1997) 403:91–94.
  • CHENG ZJ, FAN GH, ZHAO J et al.: Endogenous opioidreceptor-like receptor in human neuroblastoma SK-N-SH: activation of inhibitory G protein and homologous desensitization. NeuroReport (1997) 8:1913–1918.
  • MATHIS JP, RYAN-MORO J, CHANG A, HOM JS, SCHEIN-BERG DA, PASTERNAK GW: Biochemical evidence for orphanin FQ/nociceptin receptor heterogeneity in mouse brain. Biochem. Biophys. Res. Commun. (1997) 230:462–465.
  • CONNOR M, YEO A, HENDERSON G: The effect of nociceptin on Ca ++ channel current and intracellular Ca ++ in the SH-SY5Y human neuroblastoma cell line. Br. J. Pharmacol (1996) 118:205–207.
  • MORIKAWA H, FUKUDA K, MIMA H, SHODA T, KATO S,MORI K: Nociceptin receptor-mediated Ca2+ channel inhibition and its desensitization in NG108-15 cells. Eur. j Pharmacol. (1998) 351:247–252.
  • KNOFLACH F, REINSCHEID RK, CIVELLI O. KEMP JA:Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons. J. Neurosci. (1996) 16:6657–6664.
  • PU L, BAO GB, MA L, PEI G: Acute desensitization of nociceptin/orphanin FQ inhibition of voltage-gated calcium channels in freshly dissociated hippocampal neurons. Eur. j Neurosci. (1999) 11:3610–3616.
  • CONNOR M, CHRISTIE MJ: Modulation of Ca2+ channel currents of acutely dissociated rat periaqueductal grey neurons. J. Physiol. (Lmid.) (1998) 509:47–58.
  • ABDULLA FA, SMITH PA: Nociceptin inhibits T-type Ca2+ channel current in rat sensory neurons by a G protein-independent mechanism. J. Neurosci. (1997) 17:8721–8728.
  • VAUGHAN CW, CHRISTIE MJ: Increase by the ORL1 receptor (opioid receptor-like]) ligand, nociceptin, of inwardly rectifying potassium conductance in dorsal raphe nucleus neurons. Br. J. Pharmacol. (1996) 117:1609–1611.
  • CONNOR M, VAUGHAN CW, CHIENG B, CHRISTIE MJ: Nociceptin receptor coupling to a potassium conduc-tance in rat locus coeruleus neurons in vitro. Br. J. Pharmacol. (1996) 119:1614–1618.
  • VAUGHAN CW, INGRAM SL, CHRISTIE MJ: Actions of theORL1 receptor ligand nociceptin on membrane properties of rat periaqueductal gray neurons in vitro. Neurosci. (1997) 17:996–1003.
  • MADAMBA SG, SCHWEITZER P, SIGGINS GR: Nociceptinaugments ICE currents in hippocampal CA1 neurons by both ORL-1 and opiate receptor mechanisms. J. Neurophysiol (1999) 82:1776–1785.
  • AMANO T, MATSUBAYASHI H, TAMURA Y, TAKAHASHI T:Orphanin FQ-induced outward current in rat hippocampus. Brain Res. (2000) 853:269–274.
  • SLUGG RM, RONNEKLEIV OK, GRANDY DK, KELLY MJ:Activation of an inwardly rectifying ICE conductance by orphanin FQ/nociceptin in vasopressin-containing neurons. Neuroendocrinology (1999) 69:385–396.
  • NICOL B, LAMBERT DG, ROWBOTHAM DJ, SMART D, MCKNIGHT AT: Nociceptin induced inhibition of ICE evoked glutamate release from rat cerebral cortex. Br. Pharmacol. (1996) 119:1081–1083.
  • SINISCALCHI A, RODI D, BEANI L, BIANCHI C: Inhibitoryeffect of nociceptin on [311]-5-HT release from rat cerebral cortex slices. Br. J. Pharmacol. (1999) 128:119–123.
  • ITOH K, KONYA H, TAKAI E, MASUDA H, NAGAI K: Modification of acetylcholine release by nociceptin in conscious rat striatum. Brain Res. (1999) 845:242–245.
  • NEAL MJ, CUNNINGHAM JR, PATERSON SJ, MCKNIGHT AT: Inhibition by nociceptin of the light-evoked release of ACh from retinal cholinergic neurons. Br. J. Pharmacol. (1997) 120:1399–1400.
  • PATEL HJ, GIEMBYCZ MA, SPICUZZA L, BARNES PJ, BELVISI MG: Naloxone-insensitive inhibition of acetyl-choline release from parasympathetic nerves innervating guinea pig trachea by the novel opioid, nociceptin. Br. J. Pharmacol (1997) 120:735–736.
  • MURPHY NP, LY HT, MAIDMENT NT: Intracerebroven-tricular orphanin FQ/nociceptin suppresses dopamine release in the nucleus accumbens of anaesthetized rats. Neuroscience (1996) 75:1–4.
  • GINTZLER AR, ADAPA ID, TOLL L, MEDINA VM, WANG L: Modulation of enkephalin release by nociceptin (orphanin FQ). Eur. I Pharmacol. (1997) 325:29–34.
  • SCHLICKER E, WERTHWEIN S, KATHMANN M, BAUER U: Nociceptin inhibits noradrenaline release in the mouse brain cortex via presynaptic ORL1 receptors. Naunyn Schmiedebergs Arch. Pharmacol. (1998) 358:418–422.
  • BUCHER B: ORL1 receptor-mediated inhibition bynociceptin of noradrenaline release from perivascular sympathetic nerve endings of the rat tail artery. Naunyn Schmiedebergs Arch. Pharmacol. (1998) 358:682–685.
  • NEMETH J, HELYES Z, OROSZI G, THAN M, PINTER E, SZOLCSANYI J: Inhibition of nociceptin on sensory neuropeptide release and mast-cell plasma extravasa-tion rats. Eur.j Pharmacol. (1998) 347:101–104.
  • BRYANT W, JANIK J, BAUMANN M, CALLAHAN P: Orphanin FQ stimulates prolactin and growth hormone release in male and female rats. Brain Res. (1998) 807:228–33.
  • FABER ES, CHAMBERS JP, EVANS RH, HENDERSON G: Depression of glutamatergic transmission by nociceptin in the neonatal rat hemisected spinal cord preparation in vitro. Br. J. Pharmacol. (1996) 119:189–90.
  • LIEBEL JT, SWANDULLA D, ZEILHOFER HU: Modulation of excitatory synaptic transmission by nociceptin in superficial dorsal horn neurons of the neonatal rat spinal cord. Br. J. Pharmacol. (1997) 121:425–432.
  • SHU YS, ZHAO ZQ, LI MY, ZHOU GM: Orphanin Fq/nociceptin modulates glutamate-and kainic acid-induced currents in acutely isolated rat spinal dorsal horn neurons. Neuropeptides (1998) 32:567–571.
  • GIULIANI S, MAGGI CA: Inhibition of tachykinin release from peripheral nerve endings of sensory nerves by nociceptin, a novel opioid peptide. Br. J. Pharmacol. (1996) 118:1567–1569.
  • FISCHER A, FORSSMANN WG, UNDEM BJ: Nociceptin-induced inhibition of tachykinergic neurotransmis-sion in guinea pig bronchus. J. Pharmacol Exp. Ther. 285:902–907.
  • KYUHOU S, GEMBA H: Injection of orphanin FQ/nociceptin into the periaqueductal gray suppresses the forebrain-elicited vocalization in the guinea pig. Neurosci. Lett. (1999) 260:113–116.
  • STANFA LC, CHAPMAN V, KERR N, DICKENSON AH: Inhibitory action of nociceptin on spinal dorsal horn neurones of the rat, in vivo. Br. J. Pharmacol. 118:1875–1877.
  • •First indication that noc inhibits spinal sensitisation evoked by sustained stimulation of primary sensory afferents.
  • WANG XM, ZHANG KM, MOKHA SS: Nociceptin (orphanin FQ), an endogenous ligand for the ORLI (opioid-receptor-liken receptor, modulates responses of trigeminal neurons evoked by excitatory amino acids and somatosensory stimuli. J. Neurophysiol (1996) 76:3568–72.
  • HEINRICHER MM, MCGARAUGHTY S, GRANDY DK: Circuitry underlying anti-opioid actions of orphanin FQ in the rostral ventromedial medulla. J. Neurophysiol (1997) 78:3351–3358.
  • CHU X, XU N, LI P, WANG JQ: Profound inhibition of cardiomotor neurons in the rat rostral ventrolateral medulla by nociceptin/orphanin FQ. NeuroReport (1998) 9:1081–1084.
  • WAGNER EJ, RONNEKLEIV OK, GRANDY DK, KELLY MJ: The peptide orphanin FQ inhibits beta-endorphin neurons and neurosecretory cells in the hypothalamic arcuate nucleus by activating an inwardly-rectifying K± conductance. Neuroendocrinology (1998) 67:73–82.
  • DOT N, DUTIA MB, RUSSELL JA: Inhibition of rat oxytocin and vasopressin supraoptic nucleus neurons by nociceptin in vitro. Neuroscience (1998) 84:913–921.
  • MEIS S, PAPE HC: Postsynaptic mechanisms underlying responsiveness of amygdaloid neurons to nociceptin/orphanin FQ. J. Neurosci. (1998) 18:8133–8144.
  • KAVALIERS M, PERROT-SINAL TS: Pronociceptive effects of the neuropeptide, nociceptin, in the land snail, Cepaea nemoralis. Peptides (1996) 17:763–768.
  • MOGIL JS, GRISEL JE, REINSCHEID RK, CIVELLI O. BELKNAP JK, GRANDY DK: Orphanin FQ is a functional anti-opioid peptide. Neuroscience (1996) 75:333–337.
  • •Well-controlled analysis showing that icy. noc, rather than inducing hyperalgesia, reverses stress-induced, opioid-mediated analgesia in mice.
  • MOGIL JS, GRISEL JE, ZHANGS G, BELKNAP JK, GRANDY DK: Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ. Neurosci. Lett. (1996) 214:131–134.
  • TIAN JH, XU W, ZHANG W et al. Involvement of endoge-nous orphanin FQ in electroacupuncture-induced analgesia. NeuroReport (1997) 8:497–500.
  • OKUDA-ASHITAKA E, TACHIBANA S, HOUTANI T et al:Identification and characterization of an endogenous ligand for opioid receptor homologue ROR-C: its involvement in allodynic response to innocuous stimulus. Brain Res. Mol. Brain Res. (1996) 43:96–104.
  • •Extremely low doses of it. noc are reported to elicit nocifen-sive behaviour in mice.
  • MINAMI T, OKUDA-ASHITAKA E, NISHIZAWA M, MORI H,ITO S: Inhibition of nociceptin-induced allodynia in conscious mice by prostaglandin D2. Br. J. Pharmacol (1997) 122:605–610.
  • HARA N, MINAMI T, OKUDA-ASHITAKA E et al.: Charac-terization of nociceptin hyperalgesia and allodynia in conscious mice. Br. J. Pharmacol (1997) 121:401–408.
  • SAKURADA C, SAKURADA S, KATSUYAMA S, SASAKI J,TAN-NO K, SAKURADA T: Involvement of tachykinin NK1 receptors in nociceptin-induced hyperalgesia in mice. Brain Res. (1999) 841:85–92.
  • SAKURADA T, KATSUYAMA S, SAKURADA S et al: Nociceptin-induced scratching, biting and licking in mice: involvement of spinal NK1 receptors. Br. J. Pharmacol (1999) 127:1712–1718.
  • DAWSON-BASOA M, GINTZLER AR: Nociceptin (Orphanin FQ) abolishes gestational and ovarian sex steroid-induced antinociception and induces hyperal-gesia. Brain Res. (1997) 750:48–52.
  • INOUE M, KOBAYASHI M, KOZAKI S, ZIMMER A, UEDA H:Nociceptin/orphanin FQ-induced nociceptive responses through substance P release from periph-eral nerve endings in mice. Proc. Natl. Acad. Sci. USA (1998) 95:10949–10953.
  • •Intraplantar noc has extremely potent nociceptive activity.
  • ROSSI GC, LEVENTHAL L, PASTERNAK GW: Naloxone sensitive orphanin FQ-induced analgesia in mice. Eur. Pharmacol (1996) 311:R7–8.
  • XU XJ, HAO JX, WIESENFELD-HALLIN Z: Nociceptin orantinociceptin: potent spinal antinociceptive effect of orphanin FQ/nociceptin in the rat. NeuroReport (1996) 7:2092–2094.
  • •Intrathecal nociceptin has potent antinociceptive activity.
  • XU IS, HASHEMI M, CALO G, REGOLI D, WIESENFELD-HALLIN Z, XU XJ: Effects of intrathecal nocistatin on the flexor reflex and its interaction with orphanin FQ nociceptin. NeuroReport (1999) 10:3681–3684.
  • YAMAMOTO T, NOZAKI-TAGUCHI N, KIMURA S: Analgesic effect of intrathecally administered nociceptin, an opioid receptor-likel receptor agonist, in the rat formalin test. Neuroscience (1997) 81:249–254.
  • ERB K, LIEBEL JT, TEGEDER I, ZEILHOFER HU, BRUNE K,GEISSLINGER G: Spinally delivered nociceptin/ orphanin FQ reduces flinching behaviour in the rat formalin test. NeuroReport (1997) 8:1967–1970.
  • YAMAMOTO T, NOZAKI-TAGUCHI N, KIMURA S: Effectsof intrathecally administered nociceptin, an opioid receptor-likel (ORLO receptor agonist, on the thermal hyperalgesia induced by carageenan injection into the rat paw. Brain Res. (1997) 754:329–332.
  • NAKAGAWA T, KANEKO M, INAMURA S, SATOH M: Intracerebroventricular administration of nocistatin reduces inflammatory hyperalgesia in rats. Neurosci. Lett. (1999) 265:64–66.
  • YAMAMOTO T, NOZAKI-TAGUCHI N, KIMURA S: Effectsof intrathecally administered nociceptin, an opioid receptor-likel (ORL1) receptor agonist, on the thermal hyperalgesia induced by unilateral constric-tion injury to the sciatic nerve in the rat. Neurosci. Lett. (1997) 224:107–110.
  • ZHU CB, CAO XD, XU SF, WU GC: Orphanin FQ potenti-ates formalin-induced pain behavior and antagonizes morphine analgesia in rats. Neurosci. Lett. (1997) 235:37–40.
  • BERTORELLI R, CORRADINI L, RAFIQ K, TUPPER J, CALO G, ONGINI E: Nociceptin and the ORL1 ligand [Phe1y(CH2-NH)G1y2]nociceptin(1-13)N112 exert anti-opioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain. Br. J. Pharmacol (1999) 128:1252–1258.
  • HELYES Z, NEMETH J, PINTER E, SZOLCSANYI J: Inhibi-tion by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals. Br. J. Pharmacol (1997) 121:613–615.
  • HAO JX, XU IS, WIESENFELD-HALLIN Z, XU XJ: Anti-hyper alge sic and anti-allodynic effects of intrathecal nociceptin/orphanin FQ in rats after spinal cord injury, peripheral nerve injury and inflammation. Pain (1998) 76:385–393.
  • YAMAMOTO T, SAKASHITA Y: The role of the spinal opioid receptor likel receptor, the NK-1 receptor, and cyclooxygenase-2 in maintaining postoperative pain in the rat. Anesth. Analg. (1999) 89:1203–1208.
  • •Unlike COX-2 inhibitors, ORL1 receptor agonist may be effective for the treatment of postoperative pain.
  • ANDOH T, ITOH M, KURAISHI Y: Nociceptin gene expression in rat dorsal root ganglia induced by peripheral inflammation. NeuroReport (1997) 8:2793–2796.
  • JIA Y, LINDEN DR, SERIE JR, SEYBOLD V: Nociceptin/ orphanin FQ binding increases in superficial laminae of the rat spinal cord during persistent peripheral inflammation. Neurosci. Lett. (1998) 250:21–24.
  • ANDERBERG UM, LIU Z, BERGLUND L, NYBERG F: Plasma levels on nociceptin in female fibromyalgia syndrome patients. Z Rheumatol (1998) 57:77–80.
  • BROOKS H, ELTON CD, SMART D, ROWBOTHAM DJ, MCKNIGHT AT, LAMBERT DG: Identification of nociceptin in human cerebrospinal fluid: comparison of levels in pain and non-pain states. Pain (1998) 78:71–73.
  • FLORIN S, SUAUDEAU C, MEUNIER JC, COSTENTIN J: Nociceptin stimulates locomotion and exploratory behaviour in mice. Eur. j Pharmacol (1996) 317:9–13.
  • DEVINE DP, REINSCHEID RK, MONSMA FJ JR, CIVELLI O. AKIL H: The novel neuropeptide orphanin FQ fails to produce conditioned place preference or aversion. Brain Res. (1996) 727:225–229.
  • •An indication that noc may be devoid of abuse potential.
  • DEVINE DP, TAYLOR L, REINSCHEID RK, MONSMA FJ, JR., CIVELLI O. AKIL H: Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropep-tide orphanin FQ. Neurochem Res. (1996) 21:1387–1396.
  • SANDIN J, GEORGIEVA J, SCHOTT PA, OGREN SO, TERENIUS L: Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats. Eur. Neurosci. (1997) 9:194–197.
  • •First report of the involvement of noc in cognitive function.
  • NISHI M, HOUTANI T, NODA Y et al.: Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin/orphaninFQ receptor. EMBO J. (1997) 16:1858–1864.
  • TAKEDA H, TSUJI M, MATSUMIYA T: Changes in head-dipping behavior in the hole-board test reflect the anxiogenic and/or anxiolytic state in mice. Eur. Pharmacol (1998) 350:21–29.
  • JENCK F, MOREAU JL, MARTIN JR et al.: Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc. Natl. Acad. Sci. USA (1997) 94:14854–14858.
  • •Provides compelling evidence that noc has anxiolytic, antistress capabilities.
  • GRIEBEL G, PERRAULT G, SANGER DJ: Orphanin FQ, a novel neuropeptide with anti-stress-like activity. Brain Res. (1999) 836:221–224.
  • KOSTER A, MONTKOWSKI A, SCHULZ S et al.: Targeted disruption of the orphanin FQ/nociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc. Natl. Acad. Sci. USA (1999) 96:10444–10449.
  • POMONIS JD, BILLINGTON CJ, LEVINE AS: Orphanin FQ, agonist of orphan opioid receptor ORL1, stimulates feeding in rats. NeuroReport (1996) 8:369–371.
  • •First report that noc has orexigenic activity.
  • STRATFORD TR, HOLAHAN MR, KELLEY AE: Injections of nociceptin into nucleus accumbens shell or ventrome-dial hypothalamic nucleus increase food intake. NeuroReport (1997) 8:423–426.
  • LEVENTHAL L, MATHIS JP, ROSSI GC, PASTERNAK GW, BODNAR RJ: Orphan opioid receptor antisense probes block orphanin FQ-induced hyperphagia. Eur. Pharmacol (1998) 349:R1–3.
  • SINCHAK K, HENDRICKS DG, BAROUDI R, MICEVYCH PE: Orphanin FQ/nociceptin in the ventromedial nucleus facilitates lordosis in female rats. NeuroReport (1997) 8:3857–3860.
  • BRYANT W, JANIK J, BAUMANN M, CALLAHAN P: Orphanin FQ stimulates prolactin and growth hormone release in male and female rats. Brain Res. (1998) 807:228–233.
  • KAPUSTA DR, SEZEN SF, CHANG JK, LIPPTON H, KENIGS VA: Diuretic and antinatriuretic responses produced the endogenous opioid-like peptide, nociceptin (orphanin FQ). Life Sci. (1997) 60:PL15–21.
  • •Noc regulates water and electrolyte balance, and arterial blood pressure in the unanesthetised rat.
  • HIRAMATSU M, INOUE K: Effects of nocistatin on nociceptin-induced impairment of learning and memory in mice. Eur.j Pharmacol (1999) 367:151–155.
  • MAMIYA T, NODA Y, NISHI M, TAKESHIMA H, NABESHIMA T: Enhancement of spatial attention in nociceptin/orphanin FQ receptor-knockout mice. Brain Res. (1998) 783:236–240.
  • MAMIYA T, NODA Y, NISHI M, TAKESHIMA H, NABESHIMA T: Nociceptin system plays a role in the memory retention: involvement of naloxone benzoyl-hydrazone binding sites. NeuroReport (1999) 10:1171–1175.
  • YU TP, FEIN J, PHAN T, EVANS CJ, XIE CW: Orphanin FQ inhibits synaptic transmission and long-term potentiation in rat hippocampus. Hippocampus (1997) 7:88–94.
  • •First report that nociceptin inhibits LTP in hippocampus.
  • YU TP, XIE CW J: Orphanin FQ/nociceptin inhibits synaptic transmission and long-term potentiation in rat dentate gyrus through postsynaptic mechanisms. J. Neurophysiol (1998) 80:1277–1284.
  • MANABE T, NODA Y, MAMIYA T et al.: Facilitation of long-term potentiation and memory in mice lacking receptors. Nature (1998) 394:577–581.
  • ••Shows the ORL1 receptor is involved in cognition, andestablishes link between LTP and memory.
  • MURPHY NP, MAIDMENT NT: Orphanin FQ/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis. I Neurochern. (1999) 73:179–186.
  • DI GIANNUARIO A, PIERETTI S, CATALANI A, LOIZZO A: Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats. Neurosci. Lett. (1999) 272:183–186.
  • MURPHY NP, LEE Y, MAIDMENT NT: Orphanin FQ/nociceptin blocks acquisition of morphine place preference. Brain Res. (1999) 832:168–170.
  • •First indication that noc may have anti-addictive properties.
  • CICCOCIOPPO R, PANOCKA I, POLIDORI C, REGOLI D, MASSI M: Effect of nociceptin on alcohol intake in alcohol-preferring rats. Psychopharmacology (Bed.) (1999) 141:220–224.
  • WALKER JR, SPINA M, TERENIUS L, KOOB GF: Nociceptin fails to affect heroin self-administration in the rat. NeuroReport (1998) 9:2243–2247.
  • NARAYANAN S, MAIDMENT NT: Orphanin FQ and behavioral sensitization to cocaine. Pharmacol. Biochem. Behav. (1999) 63:271–277.
  • TIAN JH, XU W, FANG Y et al.: Bidirectional modulatory effect of orphanin FQ on morphine-induced analgesia: antagonism in brain and potentiation in spinal cord of the rat. Br. J Pharmacol (1997) 120:676–680.
  • KOTLINSKA J, SUDER P, LEGOWSKA A, ROLKA K, SILBERRING J: Orphanin FQ/nociceptin inhibits morphine withdrawal. Life Sci. (2000) 66:PL119–123.
  • UEDA H, YAMAGUCHI T, TOKUYAMA S, INOUE M, NISHI, TAKESHIMA H: Partial loss of tolerance liability to morphine tolerance in mice lacking the nociceptin receptor gene. Neurosci. Lett. (1997) 237:136–138.
  • •Noc may be involved in the development of tolerance to morphine.
  • YUAN L, HAN Z, CHANG JK, HAN JS: Accelerated release and production of orphanin FQ in brain of chronic morphine tolerant rats. Brain Res. (1999) 826:330–334.
  • GOUARDERES C, TAFANI JA, MEUNIER J-C, JHAMANDAS K, ZAJAC J-M: Nociceptin receptors in the rat spinal cord during morphine tolerance. Brain Res. (1999) 838:85–94.
  • SAITO Y, MARUYAMA K, SAIDO TC, KAWASHIMA S: Overexpression of a neuropeptide nociceptin/ orphanin FQ precursor gene, N23K/N27K, induces neurite outgrowth in mouse NS20Y cells. J. Neurosci. Res. (1997) 48:397–406.
  • •Pp-noc promotes neurone-like differentiation of neuroblas-toma cells.
  • SAITO Y, MARUYAMA K, KAWANO H et al.: Molecular cloning and characterization of a novel form of neuropeptide gene as a developmentally regulated molecule. J. Biol. Chem. (1996) 271:15615–15622.
  • IKEDA K, WATANABE M, ICHIKAWA T, KOBAYASHI T, YANO R, KUMANISHI T: Distribution of prepro-nociceptin/orphanin FQ mRNA and its receptor mRNA in developing and adult mouse central nervous systems. J. Comp. Neurol (1998) 399:139–151.
  • BUZAS B, SYMES AJ, COX BM: Regulation of nociceptin/orphanin FQ gene expression by neuropoietic cytokines and neurotrophic factors in neurons and astrocytes. J. Neurochem. (1999) 72:1882–1889.
  • •Ciliary neurotrophic factor induces pp-noc gene in neurones and astrocytes, suggesting a role of noc during development and following neural injury.
  • SHAH S, PAGE CP, SPINA D: Nociceptin inhibits non-adrenergic non-cholinergic contraction in the guinea pig airway. Br. J. Pharmacol (1998) 125:510–516.
  • RIZZI A, CALO G, TREVISANI M et al.: Nociceptin receptor activation inhibits tachykinergic non-adrenergic non-cholinergic contraction of the guinea pig isolated bronchus. Life Sci. (1998) 64:PL157–163.
  • GUMUSEL B, HAO Q, HYMAN A, CHANG JK, KAPUSTA DR, LIPPTON H: Nociceptin: an endogenous agonist for central opioid like 1 (ORL1) receptors possesses systemic vasorelaxant properties. Life Sci. (1997) 60:PL141–145.
  • CHAMPION HC, CZAPLA MA, KADOWITZ PJ: Nociceptin, an endogenous ligand for the ORL1 receptor, decreases cardiac output and total peripheral resistance in the rat. Peptides (1997) 18:729–732.
  • CZAPLA MA, CHAMPION AC, KADOWITZ PJ: Nociceptin, an endogenous ligand for the ORL1 receptor, has vasodilator activity in the hindquarters vascular bed of the rat. Peptide (1997) 18:793–795.
  • CZAPLA MA, CHAMPION AC, KADOWITZ PJ: Decreases in systemic arterial and hindquarters perfusion pressure in response to nociceptin are not inhibited by naloxone in the rat. Peptides (1997) 18:1197–1200.
  • GIULIANI S, TRAMONTANA M, LECCI A, MAGGI CA: Effect of nociceptin on heart rate and blood pressure in anaesthetized rats. Eur. j Pharm. (1997) 333:177–179.
  • CHAMPION HC, PIERCE RL, KADOWITZ PJ: Nociceptin, a novel endogenous ligand for the ORL1 receptor, dilates isolated resistance arteries from the rat. Regul Pept. (1998) 78:69–74.
  • MADEDDU P, SALIS MB, MILIA AF et al.: Cardiovascular effects of nociceptin in unanesthetized mice. Hyperten-sion (1999) 33:914–919.
  • ARNDT ML, WU D, SOONG Y, SZETO HH: Nociceptin/ orphanin FQ increases blood pressure and heart rate via sympathetic activation in sheep. Peptides (1999) 20:465–470.
  • CHAMPION HC, WANG R, HELLSTROM WJ, KADOWITZ PJ: Nociceptin, a novel endogenous ligand for the ORL1 receptor, has potent erectile activity in the cat. Am. J. Physic)]. (1997) 273:E214–219.
  • CALO G, RIZZI A, BODIN M et al.: Pharmacological characterization of nociceptin receptor: an in vitro study. Can. J. Physic)]. Pharmacol (1997) 75:713–718.
  • ZHANG G, MURRAY TF, GRANDY DK: Orphanin FQ has an inhibitory effect on the guinea pig ileum and the mouse vas deferens. Brain Res. (1997) 772:102–106.
  • YAZDANI A, TAKAHASHI T, BAGNOL D, WATSON SJ, OWYANG C: Functional significance of a newly discov-ered neuropeptide, orphanin FQ, in rat gastrointes-tinal motility. Gastroenterology (1999) 116:108–117.
  • OSINSKI MA, BASS P, GAUMNITZ EA: Peripheral and central actions of orphanin FQ (nociceptin) on murine colon. Am. J. Physic)]. (1999) 276:G125–131.
  • TANIGUCHI H, YOMOTA E, NOGI K, ONODA Y, IKEZAWA K: The effect of nociceptin, an endogenous ligand for the ORL1 receptor, on rat colonic contrac-tion and transit. Eur. j Pharmacol (1998) 353:265–271.
  • MENZIES JR, CORBETT AD: Nociceptin inhibits tonic nitric oxide release in the mouse isolated proximal colon. Eur. j Pharmacol (2000) 388:183–186.
  • KAPUSTA DR, KENIGS VA: Cardiovascular and renal responses produced by central orphanin FQ/ nociceptin occur independent of renal nerves. Am. J. Physic)]. (1999) 277:R987–95.
  • GIULIANI S, LECCI A, TRAMONTANA M, MAGGI CA: The inhibitory effect of nociceptin on the micturition reflex in anaesthetized rats. Br. J. Pharmacol (1998) 124:1566–1572.
  • BERZETEI-GURSKE IP, SCHWARTZ RW, TOLL L: Determi-nation of activity for nociceptin in the mouse vas deferens. Eur. j Pharmacol (1996) 302:R1–2.
  • CALO G, RIZZI A, BOGONI G et al.: The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur. I Pharmacol (1996) 311:R3–5.
  • ZHANG G, MURRAY TF, GRANDY DK: Orphanin FQ has an inhibitory effect on the guinea pig ileum and the mouse vas deferens. Brain Res. (1997) 772:102–106.
  • HOM JS, GOLDBERG I, MATHIS J et al.: [12511orphanin FQ/nociceptin binding in Raji cells. Synapse (1999) 34:187–191.
  • PAMPUSCH MS, OSINSKI MA, SERIE JR, MURTAUGH MP, BROWN DR: Opioid receptor gene expression in the porcine immune system. Adv. Exp. Med. Biol. (1998) 437:59–65.
  • DU LN, WU GC, CAO XD: Modulation of orphanin FQ or electroacupuncture (EA) on immune function of traumatic rats. Acupunct. Electrother. Res. (1998) 23:1–8.
  • DOOLEY CT, HOUGHTEN RA: Orphanin FQ: receptor binding and analog structure activity relationships in rat brain. Life Sci. (1996) 59:PL23–29.
  • REINSCHEID RK, ARDATI A, MONSMA FJ JR, CIVELLI O. Structure-activity relationship studies on the novel neuropeptide orphanin FQ. J. Biol. Chem. (1996) 271:14163–14168.
  • GUERRINI R, CALO G, RIZZI A et al: Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J. Med. Chem. (1997) 40:1789–1793.
  • LAPALU S, MOISAND C, MAZARGUIL H, CAMBOIS G, MOLLEREAU C, MEUNIER J-C: Comparison of the structure-activity relationships of nociceptin and dynorphin A using chimeric peptides. FEBS Lett. (1997) 417:333–336.
  • REINSCHEID RK, HIGELIN J, HENNINGSEN RA, MONSMA FJ, JR., CIVELLI O. Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities. J. Biol. Chem. (1998) 273:1490–1495.
  • DOOLEY CT, SPAETH CG, BERZETEI-GURSKE IP et al.: Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. I Pharmacol Exp. Ther. (1997) 283:735–741.
  • TOPHAM CM, MOULEDOUS L, PODA G, MAIGRET B, MEUNIER J-C: Molecular modelling of the ORL1 receptor and its complex with nociceptin. Prot. Eng. (1998) 11:1163–1179.
  • MOLLEREAU C, MOULEDOUS L, LAPALU S et al.: Distinct mechanisms for activation of the opioid receptor-like 1 and kappa-opioid receptors by nociceptin and dynorphin A. Mol Pharmacol (1999) 55:324–331.
  • GUERRINI R, CALO G, RIZZI A et al.: A new selective antagonist of the nociceptin receptor. Br. J. Pharmacol (1998) 123:163–165.
  • BUTOUR J-L, MOISAND C, MOLLEREAU C, MEUNIER J-C: [Phe1y(CH2-NH)Gly2]noc-(1-13)-amide is an agonist of nociceptin (ORL1) receptor. Eur. I Pharmacol. (1998) 349:R5–6.
  • XU IS, WIESENFELD-HALLIN Z, XU XJ: [Phely(CH2-NID-Gly2]-nociceptin-(1-13)-N1-12, a proposed antagonist of the nociceptin receptor, is a potent and stable agonist in the rat spinal cord. Neurosci. Lett. (1998) 249:127–130.
  • CARPENTER KJ, DICKENSON AH: [Phe1y(CH2-N1-1)C1Y2]-nociceptin-(1-13)-NH2, a peripheral ORL-1 receptor antagonist, acts as an agonist in the rat spinal cord. Br. Pharmacol. (1998) 125:949–951.
  • GRISEL JE, FARRIER DE, WILSON SG, MOGIL JS: [Phe1y(CH2-NH)Gly2]-nociceptin-(1-13)-NH2 acts as an agonist of the orphanin FQ/nociceptin receptor in vivo. Eur. j Pharmacol. (1998) 357:R1–3.
  • KAPUSTA DR, CHANG JK, KENIGS VA: Central admini-stration of Phe1y(CH2-NH)Gly2I-nociceptin-(1-13)-NH2 and orphanin FQ/nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats. J. Pharmacol. Exp. Ther. (1999) 289:173–180.
  • RIZZI A, BIGONI R, CALO G, GUERRINI R, SALVADORI S, REGOLI D: [Nphe1]nociceptin-(1-13)-NH2 antagonizes nociceptin effects in the mouse colon. Eur. Pharmacol. (1999) 385:R3–5.
  • HASHIMOTO Y, CALO G, GUERRINI R, SMITH G, LAMBERT DG: Antagonistic effects of [Nphe1]-nociceptin-(1-13)-NH2 on nociceptin receptor mediated inhibition of cAMP formation in Chinese hamster ovary cells stably expressing the recombi-nant human nociceptin receptor. Neurosci. Lett. (2000) 278:109–112.
  • WICHMANN J, ADAM G, ROVER S, CESURA AM, DAUTZENBERG FM, JENCK F: 8-Acenaphten-1-y1-1-phenyl-1,3,8-triza-spiro[4.5]clecan-4-one derivatives as orphanin FQ receptor agonists. Bioorg. Med. Chem. Lett. 9:2343-2348.
  • KAWAMOTO H, OZAKI S, ITOH Y et al.: Discovery of the first potent and selective small molecule opioid receptor-like (ORM) antagonist: 1-R3R,412)-1-cycloortylmethy1-3- hydroxymethy1-4-piperidy11-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one, O.113397). J. Med. Chem (1999) 42:5061–5063.
  • ••Discloses the structure and biological properties of the firstORLI receptor-selective antagonist.
  • OZAKI S, KAWAMOTO H, ITOH Y, MIYAJI M, IWASAWA Y, OHTA H: A potent and highly selective nonpeptidyl nociceptin/orphanin FQ receptor (ORM) antagonist, J-113397. Eur. J. Pharmacol (2000) 387:R17–18.
  • MOGIL JS, NESSIM LA, WILSON SG: Strain-dependent effects of supraspinal orphanin FQ/nociceptin on thermal nociceptive sensitivity in mice. Neurosci. Lett. 261:147–150.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.